Stockreport

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors [Financial Post (Toronto, Ontario, Canada)]

Genenta Science S.p.A.  (GNTA) 
PDF MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platf [Read more]